TREM2 and gastric cancer: More importantly, in GC patients, TREM2+ TAMs exclude CD8+ T cell infiltration and promote immune checkpoint expression on tumor-infiltrated CD8+ T cells, like PD-1, CTLA4, and TIM3, which shapes an inhibitory immune microenvironment.